Revolo Biotherapeutics

📍 Gaithersburg, United States🗓 Founded 2011👥 22 employees💰 Last funded 2019
Biotechnology Research🌐 revolobio.com
Website LinkedIn
Revolo Biotherapeutics is developing revolutionary therapies powered to reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases. Its two drug candidates, ‘1805 and ‘1104, a protein and a peptide respectively, reset the immune system by preventing the chronic pro-inflammatory immune response that results in autoimmune or allergic disease. ‘1805 is a modified analogue of a key molecule in immune function and is in clinical development for moderate-to-severe rheumatoid arthritis and non-infectious uveitis. ‘1104 is a peptide derived from a natural immune-regulatory protein and is in clinical development for patients with eosinophilic esophagitis (EoE) and allergic disease. The disease-agnostic mechanism of action of Revolo Biotherapeutic’s assets provides a potential platform for the development of treatments for multiple autoimmune and allergic diseases. Visit www.revolobio.com to learn more.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2011
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United Kingdom
1
Frequently asked questions
Who invested in Revolo Biotherapeutics?
Revolo Biotherapeutics has 1 investors on record on gritt.io and 1 late-stage investors.
When did Revolo Biotherapeutics last raise funding?
The most recent investment in Revolo Biotherapeutics recorded on gritt.io was in 2019.
When was Revolo Biotherapeutics founded?
Revolo Biotherapeutics was founded in 2011.
What industry is Revolo Biotherapeutics in?
Revolo Biotherapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Revolo Biotherapeutics based?
Revolo Biotherapeutics is headquartered in Gaithersburg, United States.